ICRP Publication 141: Occupational Intakes of Radionuclides: Part 4

Paquet, F.; Bailey, Michael R.; Leggett, Richard W.; Etherington, G.; Blanchardon, E.; Smith, T.; Ratia, G.; Melo, Dunstana R.; Fell, Timothy; Berkovski, V.; Harrison, John

doi:10.1177/0146645319834139

Cited by 45 publications

(14 citation statements)

References 393 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large volumes of skeletal lesions will also influence the red marrow distribution in marrow space, which may be considered for dosimetry for [177Lu]Lu-PSMA [ 175 ] and [177Lu]Lu-SSRT therapies [ 178 ]. Furthermore, any free lutetium ions in the injected drug will bind to the skeleton (60% of the activity) and be deposited in the liver (10%) [ 179 ], which can be prevented by the addition of DTPA before radiopharmaceutical administration [ 180 ].…”

Section: Dosimetry Of Organs Tissues and Tumoursmentioning

confidence: 99%

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Gleisner

Chouin

Gabiña

et al. 2022

Eur J Nucl Med Mol Imaging

104

View full text Add to dashboard Cite

The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.

show abstract

Section: Dosimetry Of Organs Tissues and Tumoursmentioning

confidence: 99%

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Gleisner

Chouin

Gabiña

et al. 2022

Eur J Nucl Med Mol Imaging

104

View full text Add to dashboard Cite

show abstract

“…The annual effective dose is a radiation protection index that quantifies the whole-body absorbed dose per year [33]. The values for the annual effective dose for all the masts in this study are lower than the ICRP permissible limits of 1.00 mSv/yr for the general public [32]. This indicates that the studied masts are in good agreement with the permissible limit.…”

Section: Resultsmentioning

confidence: 49%

“…As can be observed in Fig. 1, all the points exceeded the 0.013 mR/h recommended ambient BIR exposure level [32]. The variations in BIR can be majorly attributed to the RF radiation from the base stations.…”

Section: Resultsmentioning

confidence: 69%

“…ELCR= AEDE (mSv/y) × DL × RF 3Where AEDE is the annual effective dose equivalent, DL is the average duration of life (70 years) and RF is the fatal cancer risk factor per sievert (Sv−1). For low-dose background radiation, which is considered to produce stochastic effects, ICRP 103 uses a fatal cancer risk factor value of 0.05 for public exposure [32].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Background Radiation of Telecommunication Masts in Ebonyi State, Nigeria

Nwachukwu¹,

Ikeagwuani²,

Nwachukwu

2021

Arab Journal of Nuclear Sciences and Applications

View full text Add to dashboard Cite

In this study, the background radiation of ten selected mobile phone base stations was monitored to ascertain their radiological risk. The requirement to monitor them is because they are established contributors to background radiation. There is, therefore, often a requirement to monitor them to ascertain if their radiation levels have passed the safety standards. The study was carried out using the Radalert 100 radiation monitor and a Geographical Positioning System (Garmin GPSMAP 765). The mean background radiation exposure rate ranges from 0.0133mRhr-1to 0.0200mRhr-1. The obtained values are higher than the world standard limit of 0.013mRhr-1 recommended by ICRP. The calculated absorbed dose rates for the various base stations ranged from 115.71 nGh-1 to 174.00 nGyh-1. These values of absorbed dose rates were observed to be far higher than the world permissible value of 89 nGyh-1. The annual effective dose equivalent (AEDE) for the exposure values ranged from 0.142 mSvy-1 to 0.213 mSvy-1 which are far lower than the ICRP permissible limits of 1.00 mSvlyr for the public and implies that the base stations do not pose any immediate radiological risks. The excess lifetime cancer risk for the stations' users was all above the 0.29 × 10-3 world recommended value and therefore, suggests a possibility of the base station workers developing radiation-related illnesses over a longer time. Regular radiological monitoring of all the base stations in Ebonyi State is recommended.

show abstract

“…Biokinetic data are used to calculate the dose to organs and tissues and then to calculate the effective dose. ICRP has developed over the years a series of models describing the deposition and absorption of radionuclides in the human alimentary tract and the human respiratory tract and their distribution and retention in the body (ICRP 1994 , 2006 , 2015b , 2016b , 2017b , 2019 ).…”

Section: Long-term Researchmentioning

confidence: 99%

Areas of research to support the system of radiological protection

Laurier

Rühm

Paquet

et al. 2021

Radiat Environ Biophys

Self Cite

View full text Add to dashboard Cite

This document presents the ICRP's updated vision on “Areas of Research to Support the System of Radiological Protection”, which have been previously published in 2017. It aims to complement the research priorities promoted by other relevant international organisations, with the specificity of placing them in the perspective of the evolution of the System of Radiological Protection. This document contributes to the process launched by ICRP to review and revise the System of Radiological Protection that will update the 2007 General Recommendations in ICRP Publication 103.

show abstract

ICRP Publication 141: Occupational Intakes of Radionuclides: Part 4

Cited by 45 publications

References 393 publications

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Assessment of the Background Radiation of Telecommunication Masts in Ebonyi State, Nigeria

Areas of research to support the system of radiological protection

Contact Info

Product

Resources

About